Circulating LPS and (1→3)-β-D-Glucan: A Folie à Deux Contributing to HIV-Associated Immune Activation.
AIDS Dementia Complex
/ etiology
Anti-HIV Agents
/ therapeutic use
Bacteria
/ immunology
Bacterial Translocation
/ immunology
Biomarkers
CD4-Positive T-Lymphocytes
/ immunology
Cardiovascular Diseases
/ etiology
Cell Wall
/ chemistry
Disease Progression
Forecasting
Fungi
/ immunology
Gastrointestinal Microbiome
/ immunology
HIV Infections
/ drug therapy
Humans
Inflammation
Intestinal Mucosa
/ immunology
Lipopolysaccharides
/ blood
Lymphocyte Activation
/ immunology
Models, Immunological
Proteoglycans
beta-Glucans
/ blood
(1→3)-β-D-Glucan
HIV
LPS
antiretroviral therapy
immune activation
microbial translocation
non-AIDS events
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
11
2018
accepted:
21
02
2019
entrez:
11
4
2019
pubmed:
11
4
2019
medline:
12
9
2020
Statut:
epublish
Résumé
Immune activation is the driving force behind the occurrence of AIDS and non-AIDS events, and is only partially reduced by antiretroviral therapy (ART). Soon after HIV infection, intestinal CD4+ T cells are depleted leading to epithelial gut damage and subsequent translocation of microbes and/or their products into systemic circulation. Bacteria and fungi are the two most abundant populations of the gut microbiome. Circulating lipopolysaccharide (LPS) and (1→3)-β-D-Glucan (βDG), major components of bacterial and fungal cell walls respectively, are measured as markers of microbial translocation in the context of compromised gut barriers. While LPS is a well-known inducer of innate immune activation, βDG is emerging as a significant source of monocyte and NK cell activation that contributes to immune dysfunction. Herein, we critically evaluated recent literature to untangle the respective roles of LPS and βDG in HIV-associated immune dysfunction. Furthermore, we appraised the relevance of LPS and βDG as biomarkers of disease progression and immune activation on ART. Understanding the consequences of elevated LPS and βDG on immune activation will provide insight into novel therapeutic strategies against the occurrence of AIDS and non-AIDS events.
Identifiants
pubmed: 30967860
doi: 10.3389/fimmu.2019.00465
pmc: PMC6430738
doi:
Substances chimiques
Anti-HIV Agents
0
Biomarkers
0
Lipopolysaccharides
0
Proteoglycans
0
beta-Glucans
0
polysaccharide-K
3X48A86C8K
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
465Subventions
Organisme : Canadian Institute of Health Research
Pays : International
Références
J Endotoxin Res. 2000;6(3):205-14
pubmed: 11052175
Am J Pathol. 2001 Nov;159(5):1933-9
pubmed: 11696454
Trends Immunol. 2002 Jun;23(6):301-4
pubmed: 12072369
J Exp Med. 2002 Aug 5;196(3):407-12
pubmed: 12163569
J Immunol. 2002 Oct 1;169(7):3876-82
pubmed: 12244185
J Biomed Sci. 2003 Jan-Feb;10(1):156-66
pubmed: 12566994
J Exp Med. 2004 Sep 20;200(6):761-70
pubmed: 15365095
J Exp Med. 2004 Sep 20;200(6):749-59
pubmed: 15365096
AIDS. 2006 Jan 2;20(1):5-10
pubmed: 16327313
J Exp Med. 2006 Mar 20;203(3):497-500
pubmed: 16533891
Med Care. 2006 Aug;44(8 Suppl 2):S13-24
pubmed: 16849964
Nat Med. 2006 Dec;12(12):1365-71
pubmed: 17115046
AIDS. 2007 Feb 19;21(4):433-9
pubmed: 17301561
Diabetes. 2007 Jul;56(7):1761-72
pubmed: 17456850
J Immunol. 2007 Sep 1;179(5):3026-34
pubmed: 17709517
J Immunol. 2007 Dec 1;179(11):7385-96
pubmed: 18025182
J Med Microbiol. 2008 Mar;57(Pt 3):287-95
pubmed: 18287290
Immunobiology. 2008;213(3-4):193-203
pubmed: 18406367
AIDS. 2008 Apr 23;22(7):841-8
pubmed: 18427202
PLoS One. 2008 Jun 25;3(6):e2516
pubmed: 18575590
J Immunol. 2008 Nov 15;181(10):6687-91
pubmed: 18981083
Mucosal Immunol. 2008 Jan;1(1):23-30
pubmed: 19079157
J Allergy Clin Immunol. 2009 Jul;124(1):3-20; quiz 21-2
pubmed: 19560575
Gastroenterology. 1991 Jun;100(6):1521-7
pubmed: 2019358
Blood Purif. 2010;29(4):352-6
pubmed: 20357435
Mucosal Immunol. 2010 Jul;3(4):387-98
pubmed: 20357762
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
pubmed: 20457564
Sci Transl Med. 2010 May 19;2(32):32ra36
pubmed: 20484731
Contrib Nephrol. 2010;167:14-24
pubmed: 20519895
Curr Opin Gastroenterol. 2010 Nov;26(6):547-53
pubmed: 20693892
PLoS Pathog. 2010 Aug 19;6(8):e1001052
pubmed: 20808901
Curr Gastroenterol Rep. 2010 Dec;12(6):513-21
pubmed: 20890736
World J Gastroenterol. 2010 Nov 14;16(42):5272-9
pubmed: 21072889
J Infect Dis. 2011 Mar 15;203(6):780-90
pubmed: 21252259
J Clin Invest. 2011 Mar;121(3):1102-10
pubmed: 21317533
J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):371-9
pubmed: 21646912
Shock. 2012 Jan;37(1):63-9
pubmed: 22089201
PLoS One. 2011;6(12):e29436
pubmed: 22216281
Annu Rev Immunol. 2012;30:149-73
pubmed: 22224779
Mucosal Immunol. 2012 Nov;5(6):646-57
pubmed: 22643849
Innate Immun. 2013 Feb;19(1):10-9
pubmed: 22653750
J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):462-8
pubmed: 22972021
PLoS One. 2012;7(9):e45781
pubmed: 23049859
Clin Microbiol Rev. 2013 Jan;26(1):2-18
pubmed: 23297256
Sci Transl Med. 2013 Jul 10;5(193):193ra91
pubmed: 23843452
Immunity. 2013 Oct 17;39(4):633-45
pubmed: 24138880
Cell Host Microbe. 2013 Oct 16;14(4):387-97
pubmed: 24139398
PLoS One. 2013 Oct 16;8(10):e78146
pubmed: 24147117
Lancet Infect Dis. 2013 Nov;13(11):976-86
pubmed: 24156898
AIDS Res Ther. 2013 Dec 13;10(1):29
pubmed: 24330529
Clin Infect Dis. 2014 Jul 1;59(1):81-4
pubmed: 24704721
J Clin Invest. 2014 Jun;124(6):2802-6
pubmed: 24837437
J Infect Dis. 2014 Nov 15;210(10):1549-54
pubmed: 24864123
J Virol. 2014 Aug;88(16):8724-34
pubmed: 24899181
Front Immunol. 2014 Jul 10;5:316
pubmed: 25071777
Curr Heart Fail Rep. 2015 Apr;12(2):130-40
pubmed: 25475180
J Infect Dis. 2015 Aug 1;212(3):355-66
pubmed: 25616404
Mucosal Immunol. 2015 Jul;8(4):712-9
pubmed: 25872481
Molecules. 2015 May 27;20(6):9745-66
pubmed: 26023937
Cell. 2015 Dec 3;163(6):1444-56
pubmed: 26638073
Nat Rev Immunol. 2016 Mar;16(3):135-48
pubmed: 26898110
EBioMedicine. 2016 Jan 26;4:40-9
pubmed: 26981570
Medicine (Baltimore). 2016 Mar;95(11):e3162
pubmed: 26986173
J Clin Pathol. 1989 Mar;42(3):275-81
pubmed: 2703544
AIDS. 2016 Jun 19;30(10):1617-27
pubmed: 27045377
J Virol. 2016 Jun 10;90(13):5886-5898
pubmed: 27053552
Shock. 2016 Nov;46(5):506-518
pubmed: 27172153
EBioMedicine. 2016 Jul;9:37-44
pubmed: 27397514
Gastroenterology. 2016 Oct;151(4):616-32
pubmed: 27436072
Front Immunol. 2016 Oct 03;7:404
pubmed: 27752257
PLoS One. 2016 Oct 20;11(10):e0164978
pubmed: 27764208
GMS Infect Dis. 2015;3:
pubmed: 27917362
Transpl Infect Dis. 2017 Apr;19(2):
pubmed: 28032944
Nat Rev Microbiol. 2017 Jul;15(7):397-408
pubmed: 28461690
Front Immunol. 2017 Jul 07;8:791
pubmed: 28736555
PLoS One. 2017 Jul 27;12(7):e0181439
pubmed: 28750040
Med Mycol. 2017 Jul 1;55(5):573-578
pubmed: 28873980
Viruses. 2017 Oct 12;9(10):
pubmed: 29023371
Nat Microbiol. 2018 Jan;3(1):53-61
pubmed: 29133884
Microbiome. 2017 Nov 25;5(1):153
pubmed: 29178920
ACS Infect Dis. 2018 Jan 12;4(1):14-26
pubmed: 29207239
Nature. 2018 Jan 3;553(7686):77-81
pubmed: 29300007
J Innate Immun. 2018;10(3):189-201
pubmed: 29393221
PLoS One. 2018 Mar 30;13(3):e0194185
pubmed: 29601578
J Am Heart Assoc. 2018 May 2;7(10):null
pubmed: 29720501
Mycoses. 2018 Oct;61(10):718-722
pubmed: 29855088
Mucosal Immunol. 2018 Sep;11(5):1429-1440
pubmed: 29907866
Lancet. 2018 Aug 25;392(10148):685-697
pubmed: 30049419
Clin Infect Dis. 2019 Apr 8;68(8):1274-1281
pubmed: 30107503
Clin Infect Dis. 2018 Nov 12;:null
pubmed: 30418519
Clin Infect Dis. 2019 Mar 16;:null
pubmed: 30877304
Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10335-9
pubmed: 7937951
Clin Exp Immunol. 1993 Jun;92(3):448-54
pubmed: 8099858
Prog Clin Biol Res. 1995;392:263-72
pubmed: 8524931